<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444883</url>
  </required_header>
  <id_info>
    <org_study_id>IL49NE03</org_study_id>
    <nct_id>NCT03444883</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD</brief_title>
  <official_title>A Multicenter, Randomized, Parallel, Double Blind, Placebo-controlled Phase III Study to Evaluate Safety and Efficacy of Ilaprazole 20mg in Patients With Non-erosive Reflux Disease(NERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Ilaprazole 20 mg in
      patients with non-erosive reflux disease. This study intends to demonstrate the clinical
      superiority of Ilaprazole 20 mg to placebo administered once daily for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A mulicenter, randomized, parallel, double blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of loss of esophagitis symptom at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>Percentage of subjects who were assessed as having 'lost' the frequency and intensity of typical esophagitis symptoms by RDQ assessment at 4 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chang in esophagitis symptom score at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>The mean scores for esophagitis symptom (heartburn and/or acid regurgitation) frequency and intensity assessed with RDQ (Questions a, b/c, d) and the change in mean score across both domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PAGI-QoL score at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>The change in mean score for quality of life assessed with PAGI-QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in esophagitis symptom score according to the maximum number of rescue medication doses per day</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>The mean scores for esophagitis symptom (heartburn and/or acid regurgitation) frequency and intensity assessed with RDQ (Questions a, b/c, d) at 4 weeks of treatment versus pre-dose according to the maximum number of rescue medication doses per day and the change in mean score across both domains.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg Ilaprazole x 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10mg placebo of Ilaprazole x 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <description>10mgx2 tablet once daily for weeks</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥ 19 years and ≤ 80 years

          2. Diagnosed with non-erosive reflux disease meeting all of the following criteria:

             2-1) At least either heartburn or acid regurgitation has persisted for at least past 3
             months before screening 2-2) Have experienced at least either heartburn or acid
             regurgitation of moderate or higher intensity on at least 2 days of 7 days prior to
             initiation of the investigational product 2-3) Esophageal mucosal breaks by LA
             Classification are not observed on upper gastrointestinal endoscopy at screening

          3. Voluntarily provide written informed consent to participate in this study

        Exclusion Criteria:

          1. Esophageal stenosis, ulcerative stenosis, esophagogastric varices or Barrett esophagus
             confirmed by past upper gastrointestinal endoscopy within 1 year prior to screening

          2. Active peptic ulcer or gastrointestinal bleeding confirmed by past upper
             gastrointestinal endoscopy at screening or within 4 weeks prior to screening

          3. Abnormal value on laboratory test at screening:

             3-1) Total Bilirubin, Creatinine &gt; Upper limit of normal (ULN) x 1.5 3-2) Alkaline
             Phosphatase, BUN &gt; ULN x 2

          4. Clinically significant abnormal findings on ECG (major arrhythmia, multifocal PVC,
             second-degree or higher AV block, etc.) within 3 months prior to screening

          5. Have taken H2 receptor antagonists (H2RA), prostaglandin preparations, mucosal
             protective drugs, prokinetics, etc. within 2 weeks prior to initiation of the
             investigational product administration, or has taken PPIs within 4 weeks prior to
             initiation of the investigational product administration

          6. Expected to continuously take nonsteroidal antiinflammatory drugs (NSAIDs) including
             aspirin or steroid preparations during the study

          7. Surgical or medical condition that may significantly influence the absorption,
             distribution, metabolism or excretion of drug, including but not limited to: history
             of major gastrointestinal surgery such as gastrectomy, gastroenterostomy, colectomy,
             gastric bypass, gastric ligation or gastric banding; presence or history of active
             inflammatory bowel disease within 12 months prior to screening; has undergone critical
             surgery that may influence gastric acid secretion with exception of surgeries such as
             appendectomy, cholecystectomy, and hysterectomy

          8. Zollinger-Ellison syndrome; past history of alcoholism or drug abuse

          9. Past history of allergic symptoms (rash, fever, pruritus, etc.) or hypersensitivity to
             any ingredient of the Investigational product

         10. Past history of treated or untreated malignancy, with or without local recurrence or
             metastasis, within 5 years prior to screening (with exception of local basal cell
             carcinoma of skin)

         11. Pregnant or nursing women

         12. Women of childbearing potential who do not use proper contraception during the study

         13. Active liver disease; ALT or AST &gt; ULN x 2 at screening; or history of hepatic
             encephalopathy, esophageal varix, or portacaval shunt

         14. Receiving renal dialysis or history of kidney transplantation or presence of severe
             renal impairment (stage 4 or 5 chronic renal disease)

         15. Participated in another clinical study and took an investigational product within 3
             months prior to screening

         16. Considered by the investigator to be ineligible to participate in this study for other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Bundang-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <state>Busanjin-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeonju-si</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital, Sungkyunkwan University</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jung-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital, Buchon</name>
      <address>
        <city>Bucheon</city>
        <state>Wonmi-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yangcheon-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

